Efficacy and safety of fondaparinux in major orthopedic surgery according to the timing of its first administration

Alexander Turpie; Kenneth Bauer; Bengt Eriksson

doi:10.1055/s-0037-1613491

Thrombosis and Haemostasis, Inhaltsverzeichnis

Thromb Haemost 2003; 90(02): 364-366
DOI: 10.1055/s-0037-1613491

Letters to the Editor

Schattauer GmbH

Efficacy and safety of fondaparinux in major orthopedic surgery according to the timing of its first administration

Alexander Turpie

¹Michael Lassen, on behalf of the Steering Committees of the Pentasaccharide Orthopedic Prophylaxis Studies.

,

Kenneth Bauer

¹Michael Lassen, on behalf of the Steering Committees of the Pentasaccharide Orthopedic Prophylaxis Studies.

,

Bengt Eriksson

¹Michael Lassen, on behalf of the Steering Committees of the Pentasaccharide Orthopedic Prophylaxis Studies.

References
1 Geerts WH, Heit JA, Clagett GP. et al. Sixth ACCP Consensus Conference on anti-thrombotic therapy. Prevention of venous thromboembolism. Chest 2001; 119 Suppl 132S-75S.
2 Hull RD, Brant RF, Pineo GF. et al. Preopera-tive vs postoperative initiation of low-molecu-lar-weight heparin prophylaxis against venous thromboembolism in patients undergoingelective hip replacement. Arch Intern Med 1999; 159: 137-41.
3 Hull RD, Pineo GF, Stein PD. et al. Timing of initial administration of low-molecular-weight heparin prophylaxis against deep vein thrombosis in patients following elective hiparthroplasty. A systematic review. Arch Intern Med 2001; 161: 1952-60.
4 Hull RD, Pineo GF, Francis C. et al. for the North American Fragmin Trial Investigators. Low-molecular-weight heparin prophylaxis using dalteparin in close proximity to surgery vs warfarin in hip arthroplasty. A double-blind, randomized comparison. Arch Intern Med 2000; 160: 2199-207.
5 Strebel N, Prins M, Agnelli G, Buller HR. Preoperative or postoperative start of pro-phylaxis for venous thromboembolism with low-molecular-weight heparin in elective hip surgery?. Arch Intern Med 2002; 162: 1451-6.
6 Herbert JM, Petitou M, Lormeau JC. et al. SR 90107/Org 31540, a novel anti-factor Xa antithrombotic agent. Cardiovasc Drug Rev 1997; 15: 1-26.
7 Lassen MR, Bauer KA, Eriksson BI, Turpie AGG. for the European Pentasaccharide Hip Elective Surgery Study (EPHESUS) Steering Committee. Postoperative fondaparinux versus preoperative enoxaparin for prevention of venous thromboembolism in elective hip-replacement surgery: a randomised double-blind comparison. Lancet 2002; 359: 1715-20.
8 Turpie AGG, Bauer KA, Eriksson BI, Lassen MR. for the PENTATHLON 2000 Study Steering Committee. Postoperative fondapari-nux versus postoperative enoxaparin for pre-vention of venous thromboembolism after elective hip-replacement surgery: a random-ised double-blind trial. Lancet 2002; 359: 1721-6.
9 Bauer KA, Eriksson BI, Lassen MR. Turpie AGG for the Steering Committee of the Pentasaccharide in Major Knee Surgery Study. Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after elective major knee surgery. N Engl J Med 2001; 345: 1305-10.
10 Eriksson BI, Bauer KA, Lassen MR. Turpie AGG for the Steering Committee of the Penta-saccharide in Hip-Fracture Surgery Study. Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after hip-fracture surgery. N Engl J Med 2001; 345: 1298-304.
11 Turpie AGG, Bauer KA, Eriksson BI, Lassen MR. for the Steering Committees of the Penta-saccharide Orthopedic Prophylaxis Studies. Fondaparinux versus enoxaparin for the pre-vention of venous thromboembolism in major orthopedic surgery. A meta-analysis of 4 ran-domized double-blind studies. Arch Intern Med 2002; 162: 1833-40.
12 Bauer KA, Eriksson BI, Lassen MR. et al. Effect of age on the benefit-risk ratio of fondaparinux thromboprophylaxis in patients undergoing major orthopedic surgery. Blood 2002; 100: 278 a (abstract 1066)
13 Eriksson BI, Bergqvist D, Kälebo P. et al. Ximelagatran and melagatran compared with dalteparin for prevention of venous throm-boembolism after total hip or knee re-placement: the METHRO II randomised trial. Lancet 2002; 360: 1441-7.
14 Eriksson BI, Agnelli A, Cohen AT. et al. Direct thrombin inhibitor melagatran followed by oral ximelagatran in comparison with enoxaparin for prevention of venous thromboembolism after total hip or knee replacement. Thromb Haemost 2003; 89: 288-96.
15 Lee A, Agnelli G, Buller H. et al. Dose-response study of recombinant factor Vila/tissue factor inhibitor recombinant nematode anticoagulant protein c2 in prevention of postoperative venous thromboembolism in patients undergoing total knee replacement. Circulation 2001; 104: 74-8.
16 Fitzgerald Jr. RH, Spiro TE, Trowbridge A. et al for the Enoxaparin Clinical Trial Group. Prevention of venous thromboembolic disease following primary total knee arthroplasty. J Bone Joint Surg Am 2001; 83: 900-6.
17 Leclerc JR, Geerts WH, Desjardins L. et al. Prevention of deep vein thrombosis after ma-jor knee surgery. A randomized, double-blind trial comparing a low molecular weight hepar-in fragment (enoxaparin) to placebo. Thromb Haemost 1992; 67: 417-23.
18 Colwell Jr CW, Spiro TE, Trowbridge AA. et al. Efficacy and safety of enoxaparin versus unfractionated heparin for prevention of deep venous thrombosis after elective knee arthro-plasty. Enoxaparin Clinical Trial Group. Clin Orthop 1995; 321: 19-27.
19 Fauno P, Suomalainen O, Rehnberg V. et al. Prophylaxis for the prevention of venous thromboembolism after total knee arthroplas-ty. J Bone Joint Surg Am 1994; 76: 1814-8.
20 Colwell CW, Spiro TE, Trowbridge A. et al for the Enoxaparin Clinical Trial Group. Use of enoxaparin, a low-molecular-weight heparin, and unfractionated heparin for the prevention of deep venous thrombosis after elective hip replacement. A clinical trial com-paring efficacy and safety. J Bone Joint Surg Am 1994; 76: 3-14.